Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach

Abstract

Background Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds. Literature review This review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and from durable polymers to polymer free DES. Conclusion In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology.

Comparison of Clinical Outcomes after Non-ST-Segment and ST-Segment Elevation Myocardial Infarction in Diabetic and Nondiabetic Populations

“…In our study, reduced LVEF, cardiogenic shock, CPR on admission, peak troponin-I, NT-ProBNP, and lipid-lowering agents were common independent predictors of MACE in both the DM and non-DM groups ( Supplementary Table S5 ). These are well-known independent predictors of MACE in patients with AMI [ 33 , 43 , 44 ].…”

Bridging Nano and Body Area Networks: A Full Architecture for Cardiovascular Health Applications

“…We assume that the bio-sensor implantation procedure is based on a well-known stent technique [30], however, the stent is used here not for artery stenosis, but for creating a stable structure to mount a bio-sensor. Each stent is a tiny plastic tube (if needed, can be bioresorbable) inserted into the lumen of a blood vessel, with around 5 mm length and strut thickness of 50 µm [31].…”

Evolving Coronary Stent Technologies - A Glimpse Into the Future

“…Sirolimus is a suitable option for stent coating because of its antibacterial, antiproliferative, and immunosuppressive properties [11]. A plant-based antiproliferative and antineoplastic drug called paclitaxel is used to treat cancer [12]. First-generation stents outperformed BMS, but they were plagued by inflammatory reactions and slow artery healing, prompting the development of secondgeneration stents.…”

“…The zotarolimus and everolimus stents are based on sirolimus stents. These medications function similarly to sirolimus [12]. As the first second-generation DES, the FDA approved Medtronic's Endeavour in 2004.…”